DZ
Therapeutic Areas
Cell Source Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Veto Cell‑augmented Allogeneic HSCT | Hematologic malignancies and non‑malignant disorders | Phase 1/2 |
| Veto Cell CAR‑T for Leukemia | Acute Lymphoblastic Leukemia | Preclinical |
| Veto Cell CAR‑T for Lymphoma | Diffuse Large B‑Cell Lymphoma | Preclinical |
| Veto Cell Therapy for Type‑1 Diabetes | Autoimmune Diabetes | Preclinical |